ALK-Abelló A/S ALK-Abelló A/S

ALK-Abelló A/S

ALK-B

株式のランク #2406
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
株価
$36.03
時価総額
$7.99B
変化(1日)
-1.07%
変化(1年)
8.38%
国
DK
取引 ALK-Abelló A/S (ALK-B)

カテゴリー

Healthcare
ALK-Abelló A/S(ALK-B)の株価履歴
終値の最高値: $35.32 (2026-10-01)

終値の最安値: $2.20 (2000-03-01)
ALK-Abelló A/S の株価履歴(2000 ~ 2026)
年間株価パフォーマンス
年 パフォーマンス
2026 (TTM) 0.06%
2025 59.11%
2024 58.09%
2023 1.18%
2022 -44.26%
2021 35.05%
2020 52.05%
2019 69.02%
2018 21.48%
2017 -6.26%
2016 1.94%
2015 12.10%
2014 0.42%
2013 62.90%
2012 20.99%
2011 -3.28%
2010 -29.09%
2009 -18.50%
2008 -23.13%
2007 -41.96%
2006 116.04%
2005 -9.24%
2004 116.11%
2003 47.42%
2002 45.17%
2001 -23.57%
2000 0.00%
類似企業または競合の株価
企業 株価 変化率 1年% 国
$528.84 24.01%
US
$237.25 783.61%
US
$137.83 -3.78%
AU
$891.40 9.49%
NL
$289.06 1.56%
BE